CoagulationDisorders near Englewood, NJ

Care Philosophy: Pancreatic cancer has been my area of clinical and research focus for the past 15 years. I participated in the process of recognition that outcomes of complex surgery such as that for pancreatic cancer are better in high volume centers when performed by experienced surgeons. In 2006, I conceived, funded and built a multidisciplinary unit with the mission of improving overall outcomes in pancreatic cancer care by integrating the care of multiple medical specialists.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person nbsp;

Biography: Dr. Stoopler received his Bachelor of Science degree from Tulane University in 1971 and his medical degree from Cornell University Medical College in 1975. He completed his residency at North Shore University Hospital/Memorial Hospital and his oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York City before joining the Columbia faculty in 1980. He is a Fellow of the American College of Physicians and a member of the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, the International Society of Gastrointestinal Oncology, the American Federation for Clinical Research and the Southwest Oncology Group. Dr. Stoopler is involved in patient care, clinical research and teaching on the medical oncology service.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person nbsp;

Biography: Dr. S. Sunghyun Yoon is the Chief of the Division of Surgical Oncology and Vice-Chair of Surgical Oncology Research and Education in the Department of Surgery at Columbia University Irving Medical Center (CUIMC). Dr. Yoon is a national and international expert in the treatment of patients with sarcomas and other soft tissue tumors, gastric (stomach) and gastroesophageal cancers, gastrointestinal stromal tumors (GISTs), and melanoma. He also has over 18 years of experience in the treatment of other gastrointestinal and abdominal tumors, hepatobiliary tumors, neuroendocrine/adrenal tumors, lymphomas, and spleen tumors. He has been the principal investigator of several clinical trials examining novel treatment strategies and given numerous invited national and international lectures in relation to these cancers. Several of these trials have investigated the treatment of sarcomas, especially abdominal/retroperitoneal sarcomas, with advanced radiation techniques such as proton beam radiation and aggressive surgical resection to minimize local recurrence. Read More About These Treatments: https://columbiasurgery.org/conditions-and-treatments/retroperitoneal-sarcomas-and-pelvic-sarcomas Dr. Yoon was an early advocate for minimally invasive robotic surgery and has performed over 300 robotic procedures including robotic gastrectomies (stomach removal). He has one of the world's largest experiences in performing prophylactic total gastrectomies for patients with hereditary diffuse gastric cancer (HDGC syndrome) secondary to germline CDH1 mutation. He pioneered a technique for connection of the small bowel to the esophagus after total gastrectomy that is used by former surgical trainees and colleagues throughout the country due to its extremely low leakage rate. Dr. Yoon graduated from Harvard University and received his M.D. from the University of California at San Diego. He completed his residency in general surgery at Massachusetts General Hospital and his fellowship in surgical oncology at the Memorial Sloan-Kettering Cancer Center. He was an Associate Professor of Surgery at Massachusetts General Hospital and Harvard Medical School before joining the staff at Memorial Sloan-Kettering Cancer Center in 2012. Dr. Yoon was an Attending Surgeon in the Division of Gastric and Mixed Tumors at Memorial Sloan Kettering Cancer Center and a Professor of Surgery at Weill Cornell Medical College before joining CUIMC in 2021. Dr. Yoon's main research interests are in cancer stem cells and targeted biological agents in combination with chemotherapy and radiation therapy. His laboratory has been funded by the National Institutes of Health/National Cancer Institute for 18 years and strives to translate new research discoveries into the clinic. Dr. Yoon is also part of multi-institution research groups funded by Stand Up To Cancer and the DeGregorio Family Foundation to discover early diagnostics and new therapies for gastric cancer. His clinical and research efforts have led to over 150 original research articles, book chapters, and reviews. For a complete list of publications, please visit NCBI.

Care Philosophy: Augusta University Health is a world class health care network offering the most comprehensive care in the region where your health is our priority As leaders in patient and family centered care our physicians partner with our patients their famil

Biography: Prakash Satwani, MD specializes in the use of bone marrow transplantation to treat children and adolescents with leukemia, lymphoma, or hemophagocytic lymphohistiocytosis. Bone marrow transplantation is a dynamic, intriguing field with multiple complex issues. Dr. Satwani has always enjoyed solving puzzles and is attracted to the intellectual challenge of caring for patients whose lives may be saved or extended with bone marrow transplantation. Dr. Satwani is also inspired and motivated by the long-lasting and rich relationships formed with patients and their families, and often keeps in touch with families long after their child's treatment has been completed. Dr. Satwani teaches medical students, residents, fellows, nurses, and nurse practitioners about bone marrow transplantation. It's important to educate people so they can learn the latest advances and provide the best care possible for patients. To continue to achieve those advances, Dr. Satwani conducts clinical research in reducing the life-threatening complications related to transplantation, such as infections and graft-versus-host disease. Dr. Satwani and colleagues also evaluate reduced-intensity bone marrow transplantation preparative regimens, which use lower doses of chemotherapy with the hope of decreasing short-term and long-term complications without compromising the effectiveness of treatment.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person nbsp;

Biography: Dr. Amengual is the Herbert Irving Associate Professor of Medicine in the Division of Hematology and Oncology, Center for Lymphoid Malignancies, and Hebert Irving Comprehensive Cancer Center here at Columbia University Irving Medical Center. Dr. Amengual obtained a degree in Nutritional Sciences at Cornell University where she graduated with honors. She attained her Medical Doctorate from New York Medical College, followed by a residency in Internal Medicine at Montefiore Medical Center/Albert Einstein College of Medicine. Dr. Amengual then went on to complete her fellowship in Hematology and Oncology at the NYU Langone Medical Center, where she participated in the Physician-Scientist Training Program and graduated as a Dean's Scholar. She is the recipient of several awards and scholarships for her research, including the Irving Scholarship, the Gabrielle's Angel Foundation for Cancer Research and as a Scholar of the Amos Medical Faculty Development Award Robert Wood Johnson Foundation and the American Society of Hematology. She was also selected to participate in the prestigious American Association for Cancer Research (AACR)/American Society of Clinical Oncology (ASCO) Vail Workshop Methods in Clinical Cancer Research, the European Hematology Association/American Society of Hematology Translational Research Training Program and the South West Oncology Group (SWOG) Leadership Academy. These competitive programs select the most promising faculty for enriched development and have laid the foundation for her research. She has now served on the faculty or review committee of several of these programs. As an R01-funded physician-scientist, Dr. Amengual is focused on translating the latest scientific discoveries regarding cancer cell behavior into novel treatment platforms. She aims to translate observations and concepts developed in the laboratory directly into patient care. Specifically, she is focused on combination epigenetic targeting for both B-cell and T-cell lymphomas. She continues to develop new pharmacologic strategies directed at altering these diseases at their genetic roots, now collaborating with investigators from backgrounds of diverse scientific expertise. Dr. Amengual has been studying the effects HDAC inhibitors in combination with EZH2 inhibitors to capitalize on two common mutations driving growth of diffuse large B-cell lymphoma cells. In addition, she has studied targeting the BCL6:p53 pathway in order to shift the balance of oncogene and tumor suppressor function using novel therapeutic approaches. For T-cell lymphoma Dr. Amengual has led a clinical trial combining HDAC inhibitors with the novel antifolate drug, pralatrexate. The pralatrexate plus romidepsin combination has led to dramatic responses in patients with relapsed T-cell lymphoma and will serve as the basis of more trials to come aimed at improving outcomes with patients with these diseases. Building on these discoveries, Dr. Amengual is now evaluating the interplay of epigenetics with immune surveillance and endogenous retroviral expression in the setting of lymphoma. Dr. Amengual has lectured at academic institutions and conferences around the world, and at forums such as the Lymphoma Research Foundation and the American Hematology Society's Highlights of ASH. She has published numerous chapters and peer reviewed articles on the biology and treatment of lymphoma, and serves as a Scientific Reviewer for a number of journals in the field, including Journal of Clinical Oncology and as an Editorial Board Member of Clinical Cancer Research. She has sat on grant review and abstract review committees for meetings such as the American Society of Hematology where she has also chaired sessions, American Society of Clinical Oncology and the Doris Duke Charitable Foundation. She is actively involved in the NCI's National Clinical Trial Network, SWOG, as a Lymphoma Working Group Committee Member. Dr. Amengual is involved in numerous clinical trials for lymphoma, enabling our patients to access the best opportunities for the treatment of their disease. Dr. Amengual has clinical expertise in lymphoma, HIV- and EBV-related hematologic illnesses.